Innovative Targeting Solutions teams up with Johnson & Johnson Innovation

Biotechnology Focus reported that Vancouver-based biotech firm Innovative Targeting Solutions (ITS) has entered a research collaboration with San Francisco-based Janssen Biotech, a Johnson & Johnson subsidiary under which the companies will use ITS's proprietary HuTARG research platform to discover antibody candidates useful for modulating immune responses in autoimmunity or cancer. The HuTARG protein engineering platform engineers both T-cell receptors and fully human antibodies that bind major histocompatibility complex (MHC)/peptide complexes displaying fragments of intracellular proteins of interest. Paul Kang, CSO of Innovative Targeting Solutions Inc., says "the ability to target MHC/peptide complexes opens up an important untapped area for targeted therapy."

Read the full article here.